CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 28, 2017--
Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management
will host a conference call and live audio webcast on Thursday, May 4,
2017 at 8:00 a.m. EDT to discuss first quarter 2017 results and provide
a general business update.
To access the conference call, please dial 844-277-9450 (domestic) or
336-525-7139 (international) and reference the conference ID number
11167224. To join the live webcast, please visit the “Investors and
Media” section of the Seres website at www.serestherapeutics.com.
A webcast replay will be available on the Seres website beginning
approximately two hours after the event and will be archived for
approximately 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. is a
leading microbiome therapeutics platform company developing a novel
class of biological drugs that are designed to treat disease by
restoring the function of a dysbiotic microbiome, where the natural
state of bacterial diversity and function is imbalanced. A Phase 2 study
of Seres’ program SER-109 has been completed in multiply recurrent Clostridium difficile infection.
Seres’ clinical candidate, SER-287, is being evaluated in a Phase 1b
study in patients with mild-to-moderate ulcerative colitis (UC). Seres
is also developing SER-262, the first ever synthetic microbiome
therapeutic candidate, in a Phase 1b study in patients with primary CDI.
For more information, please visit www.serestherapeutics.com.
Follow us on Twitter @SeresTx.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170428005769/en/
Source: Seres Therapeutics, Inc.
Seres Therapeutics, Inc.
IR or PR Contact:
Carlo
Tanzi, Ph.D., 617-203-3467
Head of Investor Relations and Corporate
Communications
ctanzi@serestherapeutics.com
